Common toxicities of mammalian target of rapamycin inhibitors

Scott A. Soefje, Anand B Karnad, Andrew Brenner

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalTargeted Oncology
Volume6
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Sirolimus
Drug Therapy
Hypophosphatemia
Mucositis
Exanthema
Hyperlipidemias
Hyperglycemia
Pharmaceutical Preparations
Transplantation
Therapeutics

Keywords

  • Everolimus
  • mTOR inhibitors
  • Radaforolimus
  • Temsirolmus
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Common toxicities of mammalian target of rapamycin inhibitors. / Soefje, Scott A.; Karnad, Anand B; Brenner, Andrew.

In: Targeted Oncology, Vol. 6, No. 2, 06.2011, p. 125-129.

Research output: Contribution to journalArticle

@article{4b5e8284d61b4726aa07459d971a455d,
title = "Common toxicities of mammalian target of rapamycin inhibitors",
abstract = "The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.",
keywords = "Everolimus, mTOR inhibitors, Radaforolimus, Temsirolmus, Toxicity",
author = "Soefje, {Scott A.} and Karnad, {Anand B} and Andrew Brenner",
year = "2011",
month = "6",
doi = "10.1007/s11523-011-0174-9",
language = "English (US)",
volume = "6",
pages = "125--129",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Common toxicities of mammalian target of rapamycin inhibitors

AU - Soefje, Scott A.

AU - Karnad, Anand B

AU - Brenner, Andrew

PY - 2011/6

Y1 - 2011/6

N2 - The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.

AB - The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.

KW - Everolimus

KW - mTOR inhibitors

KW - Radaforolimus

KW - Temsirolmus

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=79960613394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960613394&partnerID=8YFLogxK

U2 - 10.1007/s11523-011-0174-9

DO - 10.1007/s11523-011-0174-9

M3 - Article

C2 - 21499766

AN - SCOPUS:79960613394

VL - 6

SP - 125

EP - 129

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -